Literature DB >> 19615744

Significant inverse correlation of microRNA-150/MYB and microRNA-222/p27 in myelodysplastic syndrome.

Kais Hussein1, Katharina Theophile, Guntram Büsche, Brigitte Schlegelberger, Gudrun Göhring, Hans Kreipe, Oliver Bock.   

Abstract

We investigated whether, in myelodysplastic syndromes (MDS), aberrant expression of miR-150/miR-221/miR-222 and their designated target mRNA molecules MYB, p27 and c-KIT may be involved in insufficient haematopoiesis. In a series of MDS (n=52), an aberrant increase of miR-150 was found only in MDS with associated del(5q) (n=9; p<0.01). The mRNA expression of transcription factor MYB, the designated target of miR-150, was shown to correlate inversely with the miR-150 level. Acute leukaemia evolving from MDS (n=11) showed significantly decreased levels of miR-221 but not miR-222. We conclude that inhibition of proliferation via over-expressed miR-150 might contribute to myelodysplastic haematopoiesis in MDS-del(5q). Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19615744     DOI: 10.1016/j.leukres.2009.06.014

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  14 in total

Review 1.  MicroRNAs as prognostic biomarker and relapse indicator in leukemia.

Authors:  S Hajizamani; M Shahjahani; S Shahrabi; N Saki
Journal:  Clin Transl Oncol       Date:  2017-03-07       Impact factor: 3.405

2.  Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome.

Authors:  Michaela Dostalova Merkerova; Zdenek Krejcik; Hana Votavova; Monika Belickova; Alzbeta Vasikova; Jaroslav Cermak
Journal:  Eur J Hum Genet       Date:  2010-12-08       Impact factor: 4.246

Review 3.  MicroRNAs in the pathogenesis of myelodysplastic syndromes and myeloid leukaemia.

Authors:  Su Jung Song; Pier Paolo Pandolfi
Journal:  Curr Opin Hematol       Date:  2014-07       Impact factor: 3.284

Review 4.  Epigenetic alterations and microRNAs: new players in the pathogenesis of myelodysplastic syndromes.

Authors:  Diamantina Vasilatou; Sotirios G Papageorgiou; George Dimitriadis; Vasiliki Pappa
Journal:  Epigenetics       Date:  2013-05-09       Impact factor: 4.528

5.  Antigen-specific, antibody-coated, exosome-like nanovesicles deliver suppressor T-cell microRNA-150 to effector T cells to inhibit contact sensitivity.

Authors:  Krzysztof Bryniarski; Wlodzimierz Ptak; Asha Jayakumar; Kerstin Püllmann; Michael J Caplan; Arthit Chairoungdua; Jun Lu; Brian D Adams; Emilia Sikora; Katarzyna Nazimek; Susanna Marquez; Steven H Kleinstein; Panjamaporn Sangwung; Yasuko Iwakiri; Eric Delgato; Frank Redegeld; Bart R Blokhuis; Jacek Wojcikowski; Anna Wladyslawa Daniel; Tom Groot Kormelink; Philip W Askenase
Journal:  J Allergy Clin Immunol       Date:  2013-05-31       Impact factor: 10.793

Review 6.  Implication of microRNAs in the pathogenesis of MDS.

Authors:  Jing Fang; Melinda Varney; Daniel T Starczynowski
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

7.  Expression patterns of microRNAs associated with CML phases and their disease related targets.

Authors:  Kateřina Machová Poláková; Tereza Lopotová; Hana Klamová; Pavel Burda; Marek Trněný; Tomáš Stopka; Jana Moravcová
Journal:  Mol Cancer       Date:  2011-04-18       Impact factor: 27.401

8.  Free Extracellular miRNA Functionally Targets Cells by Transfecting Exosomes from Their Companion Cells.

Authors:  Krzysztof Bryniarski; Wlodzimierz Ptak; Emilia Martin; Katarzyna Nazimek; Marian Szczepanik; Marek Sanak; Philip W Askenase
Journal:  PLoS One       Date:  2015-04-29       Impact factor: 3.240

Review 9.  Targeting microRNA in hematologic malignancies.

Authors:  Zhen Han; Steven T Rosen; Christiane Querfeld
Journal:  Curr Opin Oncol       Date:  2020-09       Impact factor: 3.915

10.  miR-150 inhibits terminal erythroid proliferation and differentiation.

Authors:  Zhiwei Sun; Ye Wang; Xu Han; Xielan Zhao; Yuanliang Peng; Yusheng Li; Minyuan Peng; Jianhui Song; Kunlu Wu; Shumin Sun; Weihua Zhou; Biwei Qi; Chufan Zhou; Huiyong Chen; Xiuli An; Jing Liu
Journal:  Oncotarget       Date:  2015-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.